Thrombocytopenia is a major complication of autologous bone marrow transplantation (BMT) We studied the contribution of committed progenitors and CD34+ stem cells in the autograft on the kinetics of platelet engraftment post-transplant using multi-parameter flow cytometry and colony assays. The numbers of CD34+ cell subsets, CFU-GM and CFU-Megakaryocyte (CFU-Meg) in the autograft were measured in 24 patients with breast cancer and lymphoma undergoing autologous BMT The mean numbers of progenitor cells among these patients were 1.9 × 106 CD34+ cells/kg, 0.07 106 CD34+, CD38- cells/kg; 3.2 × 104 CFU-GM/kg; 0.4 104 CFU-Meg/kg and 46 × 104 total CFU/kg. The mean and median times to achieve a platelet count of 20 x 109/1 in the absence of transfusions were 30 and 21 days, respectively. The time to platelet engraftment was correlated with the content of CD34+, CD38- cells/kg (R=-0 527, p=0.008); total CD34+ cells/kg (R=-.368, p=0.08), CFU-Meg/kg (R=-0.217, p=0.31); CFU-GM/kg (R=-0.07, p=0.74); and total CFU/kg (R=-0 08, p=0.71) The content of CD34+, CD38- progenitor cells was the best predictor of the time to achieve a platelet count of >20 x 102/l post transplant; the numbers of CFU-Meg and other committed progenitor cells were not significantly correlated with the time to platelet engrafbnent. We conclude that the content of pluripotent stem cells, as assessed by multi-parameter flow cytometry of CD34+ subsets, yields clinically relevant data that help predict hematopoietic engraftment following autologous BMT.
|Original language||English (US)|
|Number of pages||1|
|State||Published - Dec 1 1997|
ASJC Scopus subject areas
- Molecular Biology
- Cell Biology
- Cancer Research